J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
Betsy Goodfellow | February 12, 2024 | News story | Medical Communications | Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn (HDFN).
The drug is the only therapy currently in development for this indication, which is a rare condition that can occur when the blood types of a pregnant individual and the foetus are incompatible, leading to potentially life-threatening anaemia in the foetus or infant.
This designation follows data from the proof-of-concept phase 2 open-label UNITY clinical trial, which met its primary endpoint of the majority of pregnant patients receiving the drug achieving a live birth at or after a gestational age of 32 weeks without needing an intrauterine transfusion (IUT) throughout their pregnancy.
Severe or serious adverse events were generally low and remained consistent with events associated with pregnancy, HDFN and gestational age at birth.
Katie Abouzahr MD, vice president, autoantibody and maternal foetal immunology Disease Area Leader at J&J, commented: “Nipocalimab represents a novel approach for the treatment of patients at risk of severe HDFN who need proven, safe, non-surgical solutions to help address the serious health consequences of this condition. We are committed to addressing the substantial unmet need in this devastating disease.”
Betsy Goodfellow
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
